{"id":11188,"date":"2025-10-02T14:50:09","date_gmt":"2025-10-02T14:50:09","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/oncologic-hyperthermia-phase-3-trials\/"},"modified":"2025-10-03T08:50:33","modified_gmt":"2025-10-03T08:50:33","slug":"hypertermia-fase-3-studier","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/da\/hypertermia-fase-3-studier\/","title":{"rendered":"Terapeutisk Integration af Hypertermi i Moderne Onkologi: En Kritisk Analyse af Fase III-Studier og Meta-Analyser (OS, DFS, CR Endpoints)"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Terapeutisk Integration af Hypertermi i Moderne Onkologi: En Kritisk Analyse af Fase III-Studier og Meta-Analyser (OS, DFS, CR Endpoints)\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Andromedichyperthermia Center\"\n        }\n      },\n      \"keywords\": \"Hypertermi, Onkologi, Fase III-fors\u00f8g, overlevelse, OS, komplet respons, CR, Sarkom, Livmoderhalskr\u00e6ft, E-E-A-T\"\n      \/* ... Schema FAQPage would be added separately for the FAQ section *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong>Autoritet og Ekspertise (E-E-A-T):<\/strong><br \/>\n<strong>Af Dr. Veronica Iatan, MD, og Cristian Gologan M.S.c, Andromedichyperthermia<\/strong><\/div>\n<h1>Terapeutisk Integration af Hypertermi i Moderne Onkologi: En Kritisk Analyse af Fase III-Studier og Meta-Analyser (OS, DFS, CR Endpoints)<\/h1>\n<h2>1. Resum\u00e9 og Grundl\u00e6ggende Principper for Hypertermi (HT)<\/h2>\n<p>Onkologisk <strong>Hypertermi (HT)<\/strong>, defineret som den kontrollerede anvendelse af varme ved temperaturer i intervallet <strong>39\u00b0C til 45\u00b0C<\/strong>, repr\u00e6senterer en adjuvant terapeutisk modalitet, der har <strong>demonstreret en betydelig klinisk fordel, bekr\u00e6ftet af Level 1A-evidens<\/strong> (<strong>Fase III randomiserede studier og meta-analyser<\/strong>), for en r\u00e6kke avancerede og recidiverende solide tumorer.<\/p>\n<div class=\"key-points\">\n<h3>N\u00f8gleindsigter &#8211; Level 1A-Evidens:<\/h3>\n<ul>\n<li><strong>Rolle:<\/strong> HT \u00f8del\u00e6gger ikke tumoren direkte; den fungerer som en kraftfuld <strong>biologisk sensibilisator<\/strong>.<\/li>\n<li><strong>Bekr\u00e6ftede Fordele:<\/strong> Syntese af Level 1A-data fremh\u00e6ver en konsekvent forbedring i <strong>Overall Survival (OS)<\/strong> og <strong>Complete Response Rate (CR)<\/strong>.<\/li>\n<li><strong>Hovedindikationer:<\/strong> Bl\u00f8ddelssarkomer, livmoderhalskr\u00e6ft, recidiverende brystkr\u00e6ft, malignt melanom, bl\u00e6rekr\u00e6ft, endetarmskr\u00e6ft (rektal cancer) og Hoved- og Hals (HNC) tumorer.<\/li>\n<li><strong>Sikkerhed:<\/strong> Denne robuste terapeutiske fordel opn\u00e5s konsekvent <strong>uden en signifikant stigning i systemisk toksicitet eller alvorlige bivirkninger<\/strong> (Grad 3 eller 4).<\/li>\n<li><strong>Konklusion:<\/strong> HT er et uundv\u00e6rligt adjuvans i standard multimodale behandlingsregimer for udvalgte tumorer.<\/li>\n<\/ul>\n<\/div>\n<h3>1.1. Klassifikation og Modaliteter inden for Onkologisk Hypertermi<\/h3>\n<h4>1.1.1. Lokoregional Hypertermi (L-R HT)<\/h4>\n<p>Dette bruges til dyb opvarmning af b\u00e6kken-, thorax- og abdominale tumorer. Almindelige teknikker omfatter kapacitive radiofrekvens (RF) systemer og radiative systemer med antenne-array matching. M\u00e5let er den mest homogene (isothermiske) opvarmning af hele tumormassen.<\/p>\n<h4>1.1.2. RF-Moduleret Hypertermi (mHT)<\/h4>\n<p>Moduleret RF Hypertermi (mHT) repr\u00e6senterer en distinkt non-invasiv tilgang. I mods\u00e6tning til traditionel isotermisk opvarmning anvender mHT en kapacitiv kobling ved en b\u00e6refrekvens p\u00e5 13,56 MHz, moduleret af fraktale fluktuationer over tid. Denne &#8220;opvarmning indefra og ud&#8221;-mekanisme resulterer i h\u00f8jere intratumorale temperaturer og reduceret skade p\u00e5 normalt v\u00e6v.<\/p>\n<h4>1.1.3. Interstitiel Hypertermi<\/h4>\n<p>Denne modalitet involverer invasiv levering af varme, ofte gennem antenner, st\u00e6nger eller &#8220;fr\u00f8&#8221; (seeds) indsat direkte i tumoren. Den bruges prim\u00e6rt til behandling af hjernetumorer (gliomer) eller recidiverende overfladisk sygdom.<\/p>\n<h3>1.2. Hvorfor Virker det Terapeutiske Vindue p\u00e5 39-45\u00b0C? (Biologiske Mekanismer)<\/h3>\n<p>Den kliniske effektivitet, demonstreret af HT p\u00e5 Fase III-niveau, er uadskillelig fra forst\u00e5elsen af dens komplekse biologiske mekanismer. Disse mekanismer overskrider simpel celle\u00f8del\u00e6ggelse og positionerer HT som en <strong>multifunktionel sensibilisator<\/strong> af standardbehandlinger. Den optimale temperatur p\u00e5 <strong>39-45\u00b0C<\/strong> v\u00e6lges, fordi den maksimerer tumorspecifikke cellul\u00e6re ubalancer.<\/p>\n<hr \/>\n<h2>2. Virkningsmekanismer: Hvordan Forst\u00e6rker Hypertermi Onkologiske Behandlinger?<\/h2>\n<p>Den overlegne kliniske effektivitet af kombineret terapi er resultatet af robust biologisk synergi, der m\u00e5lretter tumorresistens p\u00e5 flere niveauer.<\/p>\n<h3>2.1. Radiosensibilisering: Overvindelse af Tumorresistens og DNA-reparation<\/h3>\n<p>Hypertermi er anerkendt som en potent radiosensibilisator, der adresserer to af de mest betydelige kilder til str\u00e5lebehandlingssvigt:<\/p>\n<ol>\n<li><strong>H\u00e6mning af DNA-reparation:<\/strong> HT h\u00e6mmer DNA-reparationsmekanismer beskadiget af str\u00e5ling.<\/li>\n<li><strong>Iltning af Mikromilj\u00f8et:<\/strong> HT \u00f8ger blodgennemstr\u00f8mningen og forbedrer tumoriltningen, hvilket reducerer den hypoksiske (str\u00e5leresistente) fraktion.<\/li>\n<\/ol>\n<h3>2.2. Kemisensibilisering: Forbedring af L\u00e6gemiddeltrafik og Cellul\u00e6r Optagelse<\/h3>\n<h4>2.2.1. Synergi og Additivitet med N\u00f8glemidler<\/h4>\n<p>HT demonstrerer st\u00e6rke synergistiske effekter med platinbaserede midler (Cisplatin, Carboplatin) og Mitomycin C, som ofte anvendes i Fase III-indikationer (f.eks. livmoderhalskr\u00e6ft og HNC-tumorer).<\/p>\n<h4>2.2.2. Farmakokinetisk Forst\u00e6rkning<\/h4>\n<p>HT optimerer l\u00e6gemiddellevering til tumorniveauet ved at \u00f8ge l\u00e6gemiddeltrafikken ind i tumorer og lymfeknuder (LN). Dette skyldes \u00f8get perfusion og modifikation af den cellul\u00e6re membranpermeabilitet.<\/p>\n<h3>2.3. Immunomodulation: Forvandling af en &#8220;Kold&#8221; Tumor til en &#8220;Varm&#8221; (Immunogen) Tumor<\/h3>\n<p>HT fungerer som en &#8220;in situ tumorvaccine&#8221; ved at inducere frigivelsen af Heat Shock Proteins (HSP&#8217;er) og tumorantigener, hvilket aktiverer dendritiske celler (DC&#8217;er) og <strong>&#8220;primer&#8221; cytotoksiske CD8+ T-celler<\/strong>. Denne proces forvandler effektivt immunologisk &#8220;kolde&#8221; tumorer til <strong>&#8220;varme&#8221; (inflammerede)<\/strong> tumorer.<\/p>\n<p><strong>Tabel 1: Mekanismer for Interaktion af Hypertermi med Standard Onkologiske Terapier<\/strong><\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>M\u00e5lmekanisme<\/strong><\/td>\n<td width=\"104\"><strong>Biologisk Effekt (39 C &#8211; 45 C)<\/strong><\/td>\n<td width=\"104\"><strong>Terapeutisk Synergi<\/strong><\/td>\n<td width=\"104\"><strong>Synergistiske Midler<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">H\u00e6mning af DNA-reparation<\/td>\n<td width=\"104\">H\u00e6mmer DNA-reparationsmekanismer;<\/td>\n<td width=\"104\">Potent Radiosensibilisator (Komplementerer RT)<\/td>\n<td width=\"104\">Str\u00e5lebehandling (RT)<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Tumormikromilj\u00f8<\/td>\n<td width=\"104\">\u00d8ger blodgennemstr\u00f8mningen, forbedrer tumoriltningen, \u00f8ger vaskulariseringen<\/td>\n<td width=\"104\">Forst\u00e6rker RT&#8217;s effektivitet; Forbedrer l\u00e6gemiddeltrafik (Kemisensibilisator)<\/td>\n<td width=\"104\">RT, Cisplatin, Mitomycin C<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cellemembran\/Struktur<\/td>\n<td width=\"104\">\u00d8get dielektrisk tab; Direkte apoptotisk signalering<\/td>\n<td width=\"104\">Forbedret l\u00e6gemiddelabsorption;<\/td>\n<td width=\"104\">Cisplatin, Carboplatin, Bleomycin<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Immunsystem<\/td>\n<td width=\"104\">HSP-frigivelse, DC-aktivering, T-celle &#8220;priming&#8221;<\/td>\n<td width=\"104\">Tumor Immunmodulator; Forst\u00e6rket Anti-Tumor Immunitet<\/td>\n<td width=\"104\">Immunoterapi, RT, CHT<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<figure id=\"attachment_11120\" aria-describedby=\"caption-attachment-11120\" style=\"width: 747px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11120 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie.jpg\" alt=\"biologiske mekanismer hypertermi\" width=\"747\" height=\"412\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie.jpg 747w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie-300x165.jpg 300w\" sizes=\"auto, (max-width: 747px) 100vw, 747px\" \/><figcaption id=\"caption-attachment-11120\" class=\"wp-caption-text\">biologiske mekanismer hypertermi<\/figcaption><\/figure>\n<hr \/>\n<h2>3. Syntese af Level 1A-Evidens: Resultater af Meta-Analyser og Aggregerede Data<\/h2>\n<p><strong>En syntese af Level 1A-evidens bekr\u00e6fter en generaliseret klinisk fordel ved HT tilf\u00f8jet standardterapi i flere tumor kategorier.<\/strong><\/p>\n<h3>3.1. Overblik over Meta-Analytiske Konklusioner<\/h3>\n<p><strong>Fem ud af seks lokoregionale HT-studier<\/strong> i en nylig analyse demonstrerede \u00f8get <strong>Overall Survival (OS)<\/strong> og\/eller forbedret <strong>Complete Response Rate (CR)<\/strong> ved at tilf\u00f8je HT til standard kemoterapi og\/eller str\u00e5lebehandling[2].<\/p>\n<h3>3.2. Kvantificering af Overall Survival (OS), Complete Response (CR) og Lokal Kontrol<\/h3>\n<p>Aggregerede data for <strong>Lokalt Fremskreden Livmoderhalskr\u00e6ft (LACC)<\/strong> demonstrerer:<\/p>\n<ul>\n<li><strong>Complete Response (CR):<\/strong> CR-raten \u00f8ges signifikant (Relativ Risiko &#8211; <strong>RR p\u00e5 0,56<\/strong>, 95% CI 0.39 til 0.79; *p &lt; 0,001*).<\/li>\n<li><strong>Lokal Recidiv Kontrol:<\/strong> HT reducerer signifikant den Lokale Recidiv Rate (Hazard Ratio &#8211; <strong>HR p\u00e5 0,48<\/strong>, 95% CI 0.37 til 0.63; *p &lt; 0,001*).<\/li>\n<li><strong>Overall Survival (OS):<\/strong> Multimodal behandling med HT medf\u00f8rer bedre OS (HR p\u00e5 <strong>0,67<\/strong>, 95% CI 0.45 til 0.99; *p = 0,05*).<\/li>\n<\/ul>\n<hr \/>\n<h2>4. Analyse af Specifikke Fase III-Studier efter Kr\u00e6fttype<\/h2>\n<h3>4.1. Bl\u00f8ddelssarkom (STS)<\/h3>\n<p>Bl\u00f8ddelssarkom er en af benchmark-indikationerne for HT. Studier har vist, at *tilf\u00f8jelsen af HT f\u00f8rte til \u00f8get overlevelse og forbedret lokal progressionsfri overlevelse (LPFS)*. Overs\u00e6ttelsesanalyse viste, at kombineret terapi transformerede en ikke-inflammeret tumor til en inflammeret tumor.<\/p>\n<h3>4.2. Gyn\u00e6kologisk Kr\u00e6ft: Lokalt Fremskreden Livmoderhalskr\u00e6ft (LACC)<\/h3>\n<h4>4.2.2. Kvantificering af Overall Survival (OS)<\/h4>\n<p><strong>Overall Survival (OS) blev signifikant forbedret ved at kombinere CCRT med HT, med en HR p\u00e5 0,67 (95% CI 0.45 til 0.99; p = 0,05).<\/strong> Historiske Fase III-resultater viste en sl\u00e5ende forskel: CR-raten i den kombinerede behandlingsgruppe var *82,3%* versus *36,8%* i gruppen behandlet med str\u00e5lebehandling alene. En langtidsoverlevelsesanalyse rapporterede *en 5-\u00e5rs Overall Survival p\u00e5 55%* versus *0%* i hypertermi-armen versus str\u00e5ling alene-armen [3,4].<\/p>\n<h4>4.2.3. Yderligere Evidens (OS)<\/h4>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"208\">Klinisk Indikator<\/td>\n<td width=\"208\">Opn\u00e5et Resultat med RT + Hypertermi<\/td>\n<td width=\"208\">Reference (Gennemg\u00e5ede Citater)<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"208\"><strong>Complete Response (CR)<\/strong><\/td>\n<td width=\"208\">Konsekvent forbedring i CR-raten: <strong>+22,1%<\/strong> sammenlignet med simpel RT.<\/td>\n<td width=\"208\">Meta-analyser<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Lokoregional Kontrol (LRC)<\/strong><\/td>\n<td width=\"208\">Signifikant forbedring: <strong>+23,1%<\/strong> sammenlignet med simpel RT.<\/td>\n<td width=\"208\">Meta-analyser<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Overall Survival (OS)<\/strong><\/td>\n<td width=\"208\">En forbedring i langsigtet OS blev observeret (HR 0,67; p = 0,03) med tilf\u00f8jelsen af Hypertermi.<\/td>\n<td width=\"208\">Opdateret meta-analyse<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Disease-Free Survival (DFS)<\/strong><\/td>\n<td width=\"208\">Signifikant forbedring i 2- og 3-\u00e5rs DFS, n\u00e5r det kombineres med CTRT.<\/td>\n<td width=\"208\">Fase III randomiserede studier<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h5>4.2.3.1. Meta-analyse: CR, Lokoregional Kontrol (LRC) og Overall Survival (OS) (Lutgens et al.)<\/h5>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Bekr\u00e6ftede Indikatorer<\/td>\n<td width=\"312\">N\u00f8glereultat<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>Complete Response (CR)<\/strong><\/td>\n<td width=\"312\">Signifikant forbedring (RR 0,56; p &lt; 0,001)<\/td>\n<\/tr>\n<tr>\n<td width=\"312\"><strong>Lokoregional Kontrol (LRC)<\/strong><\/td>\n<td width=\"312\">Signifikant forbedring (HR 0,48; p &lt; 0,001)<\/td>\n<\/tr>\n<tr>\n<td width=\"312\"><strong>Overall Survival (OS)<\/strong><\/td>\n<td width=\"312\">Signifikant forbedring efter 3 \u00e5r (HR 0,67; p = 0,05)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Titel:<\/strong> Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma<\/li>\n<li><strong>Forfattere:<\/strong> Lutgens L, van der Zee J, Pijls-Johannesma M, et al.<\/li>\n<li><strong>PubMed Link (2010 Update):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20091593\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20091593\/<\/a><\/li>\n<\/ul>\n<h5>4.2.3.2. Netv\u00e6rksmeta-analyse (NMA): Bedste Strategier (Datta et al. 2019)<\/h5>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Bekr\u00e6ftede Indikatorer<\/td>\n<td width=\"312\">N\u00f8glereultat<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>Behandlingsrangering<\/strong><\/td>\n<td width=\"312\"><strong>RT+HT<\/strong> og <strong>CTRT+HT<\/strong> rangeret blandt de tre bedste interventioner med den bedste omfattende effekt p\u00e5 LRC, OS og toksicitet.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Titel:<\/strong> Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials<\/li>\n<li><strong>Forfattere:<\/strong> Datta NR, Stutz E, Gomez S, Bodis S.<\/li>\n<li><strong>PubMed Link:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30391522\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30391522\/<\/a><\/li>\n<\/ul>\n<h5>4.2.3.3. Fase III-Studie: Disease-Free Survival (DFS) og QoL med mEHT<\/h5>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Bekr\u00e6ftede Indikatorer<\/td>\n<td width=\"312\">N\u00f8glereultat<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>Disease-Free Survival (DFS)<\/strong><\/td>\n<td width=\"312\">Signifikant forbedring i 2- og 3-\u00e5rs DFS med tilf\u00f8jelsen af mEHT til CTRT.<\/td>\n<\/tr>\n<tr>\n<td width=\"312\"><strong>Livskvalitet (QoL)<\/strong><\/td>\n<td width=\"312\">Signifikant QoL-forbedring uden \u00f8get toksicitet.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Titel:<\/strong> Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients<\/li>\n<li><strong>Forfattere:<\/strong> Minnaar CA, Maposa I, Kotzen JA, et al.<\/li>\n<li><strong>MDPI Link (Fuld Tekst Tilg\u00e6ngelig):<\/strong> <a href=\"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/656\" target=\"_blank\" rel=\"noopener\">https:\/\/www.mdpi.com\/2072-6694\/14\/3\/656<\/a><\/li>\n<\/ul>\n<h3>4.3. Hoved- og Halskr\u00e6ft (HNC)<\/h3>\n<h4>4.3.1. Fase III Randomiserede Studiedata<\/h4>\n<p><strong>Prospektive, randomiserede Fase III-studier har dokumenteret klare fordele ved at kombinere kemostr\u00e5leterapi (CRT) med HT versus CRT alene.<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><strong>Kang 2013<\/strong><\/a> <strong>(NPC):<\/strong> 5-\u00e5rs Disease-Free Survival (DFS) *steg fra 25,5% til 51,3% (p &lt; 0,005), og 5-\u00e5rs OS **steg fra 50% til 68,4% (p &lt; 0,005)*. CR-raten steg fra 62,8% til 81,6%.<\/li>\n<li><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><strong>Huilgol 2010<\/strong><\/a> <strong>(Mundhule\/Sv\u00e6lg):<\/strong> Komplet respons blev observeret i *42,4%* af str\u00e5lebehandling alene-gruppen, sammenlignet med *78,6%* i den HT-behandlede gruppe.<\/li>\n<\/ul>\n<h3>4.4. Mave-Tarm Kr\u00e6ft: Endetarms- og Analkr\u00e6ft<\/h3>\n<h4>4.4.1. Fase III Resultater i Endetarmskr\u00e6ft (Rektal Cancer)<\/h4>\n<p>Det prospektive randomiserede studie <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong>Ott 2019<\/strong><\/a> sammenlignede CRT med CRT + HT og rapporterede signifikante 5-\u00e5rs forbedringer i HT-armen:<\/p>\n<ul>\n<li><strong>Overall Survival (OS): 95,8% vs. 74,5% (P = 0,045).<\/strong><\/li>\n<li><strong>Disease-Free Survival (DFS): 89,1% vs. 70,4% (P = 0,027).<\/strong><\/li>\n<li><strong>Lokal Recidivfri Overlevelse (LRFS): 97,7% vs. 78,7% (P = 0,006)<\/strong>.<\/li>\n<\/ul>\n<p>Dette studie fremh\u00e6ver HT&#8217;s rolle i *lukkemuskelbevarende strategier* (87,7% vs. 69,0% for kolostomi-fri overlevelse).<\/p>\n<h3>4.5. Malignt Melanom (Lokoregional Sygdom)<\/h3>\n<p>Grundl\u00e6ggende Fase III-forskning (<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><strong>Overgaard et al., 1995<\/strong><\/a>) har vist, at kombinationen af str\u00e5lebehandling med HT forbedrer Lokal Kontrol og OS i fremskredent melanom.<\/p>\n<h5>1. Lokal Tumor Kontrol (Prim\u00e6rt Endepunkt)<\/h5>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"156\">Endepunkt<\/td>\n<td width=\"156\">Str\u00e5lebehandling Alene (RT)<\/td>\n<td width=\"156\">Str\u00e5lebehandling + Hypertermi (RT + HT)<\/td>\n<td width=\"156\">N\u00f8gleforskel<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"156\"><strong>Aktuarisk Lokal Kontrol efter 2 \u00c5r<\/strong><\/td>\n<td width=\"156\"><strong>28%<\/strong><\/td>\n<td width=\"156\"><strong>46%<\/strong><\/td>\n<td width=\"156\"><strong>Signifikant forbedring (p = 0,008)<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Konklusion:<\/strong> Tilf\u00f8jelsen af HT forbedrede lokal tumor kontrol med *18 procentpoint* efter 2 \u00e5r.<\/li>\n<\/ul>\n<h5>4.6 Recidiverende Brystkr\u00e6ft<\/h5>\n<h4>4.6.1. Meta-analyse, der bekr\u00e6fter effektiviteten af termoradioterapi i recidiverende brystkr\u00e6ft<\/h4>\n<p>En meta-analyse konsoliderer data, der viser, at Termoradioterapi (RT + Hypertermi) \u00f8ger Complete Response-raten (CR) med cirka *22%* sammenlignet med str\u00e5lebehandling alene; i studier, der sammenlignede de to behandlingsarme, blev en CR-rate p\u00e5 *60,2%* opn\u00e5et med RT + Hypertermi (HT), sammenlignet med 38,1% med RT alene, og n\u00e5ede en CR-rate p\u00e5 *66,6%* i tilf\u00e6lde af genbestr\u00e5ling med hypertermi.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis.<\/strong><\/a><\/li>\n<\/ul>\n<h4>4.6.2 Thorakalt Recidiv af Brystkr\u00e6ft<\/h4>\n<p>HT i kombination med RT har Level 1A-evidens for behandling af thorakalt recidiv af brystkr\u00e6ft. Studier viser h\u00f8je Komplet Respons Rater (CR), der sp\u00e6nder fra 40% til 86%, og Lokale Kontrol Rater (LC) mellem 70% og 76%.<\/p>\n<p><strong>Tabel 2: N\u00f8gle Fase III Kliniske Resultater for Hypertermi i Onkologi (HT + Standard Pleje vs. Standard Pleje Alene)<\/strong><\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Kr\u00e6fttype (HT Modalitet)<\/strong><\/td>\n<td width=\"104\"><strong>Studietype\/Endepunkt<\/strong><\/td>\n<td width=\"104\"><strong>HT + Standard Pleje<\/strong><\/td>\n<td width=\"104\"><strong>Standard Pleje Monoterapi<\/strong><\/td>\n<td width=\"104\"><strong>Statistisk Signifikans\/Endepunkt Resultat<\/strong><\/td>\n<td width=\"104\"><strong>Reference<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Bl\u00f8ddelssarkom (L-R HT + CT) 11,3 \u00e5r<\/td>\n<td width=\"104\">Fase III Randomiseret (5-\u00e5rs OS, 10-\u00e5rs OS)<\/td>\n<td width=\"104\">62,7% \/ 52,6%<\/td>\n<td width=\"104\">51,3% \/ 42,7%<\/td>\n<td width=\"104\">Forbedret *Overall Survival OS* (HR, 0,73; P = 0,04); Forbedret *DFS* (HR, 0,65; P = 0,002).<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Livmoderhalskr\u00e6ft (LACC) (L-R HT + RT) 12 \u00e5r<\/td>\n<td width=\"104\">Fase III Randomiseret (<strong>12-\u00e5rs OS<\/strong>)<\/td>\n<td width=\"104\">37%<\/td>\n<td width=\"104\">20%<\/td>\n<td width=\"104\">Signifikant bedre OS (P &lt; 0,05)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Endetarmskr\u00e6ft (CRT + HT) 5 \u00e5r<\/td>\n<td width=\"104\">Fase III Randomiseret (<strong>5-\u00e5rs OS<\/strong>, 5-\u00e5rs DFS, 5-\u00e5rs lokal recidivfri LRF, 5-\u00e5rs kolostomi-fri overlevelse CFSR)<\/td>\n<td width=\"104\">95,8% \/ 89,1% \/ 97,7% \/ 87,7%<\/td>\n<td width=\"104\">74,5% \/ 70,4% \/ 78,7% \/ 69,0%<\/td>\n<td width=\"104\">Forbedret OS (P = 0,045), DFS (P = 0,027), LRF (P = 0,006), CFSR (P = 0,016)<\/td>\n<td width=\"104\"><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Hoved- og Halskr\u00e6ft NPC (CRT + HT)<\/td>\n<td width=\"104\">Fase III Randomiseret (5-\u00e5rs DFS og 5-\u00e5rs OS og CR )<\/td>\n<td width=\"104\">51,3% \/ 68,4% \/ 81,6%<\/td>\n<td width=\"104\">25,5% \/ 50% \/ 62,8%<\/td>\n<td width=\"104\">Signifikant forbedring.<\/td>\n<td width=\"104\"><strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\">Kang 2013<\/a><\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Malignt Melanom (RT + HT)<\/td>\n<td width=\"104\">Fase III Randomiseret (CR)<\/td>\n<td width=\"104\">46%<\/td>\n<td width=\"104\">28%<\/td>\n<td width=\"104\">Signifikant forbedring i 2-\u00c5rs Aktuarisk Lokal Kontrol (p = 0,008)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Recidiverende Brystkr\u00e6ft (RT + HT) &#8211; HT inkluderet i NCCN-retningslinjer<\/td>\n<td width=\"104\">Fase III Randomiseret (CR)<\/td>\n<td width=\"104\">60,2%<\/td>\n<td width=\"104\">38,1%<\/td>\n<td width=\"104\">CR-raten steg med 57% relativt<\/td>\n<td width=\"104\"><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Bl\u00e6rekr\u00e6ft IR NMI (HIVEC-1)<\/td>\n<td width=\"104\">Fase III Randomiseret (24-m\u00e5neders RFS)<\/td>\n<td width=\"104\">80%-82%<\/td>\n<td width=\"104\">77%<\/td>\n<td width=\"104\">Ingen signifikant forskel (p = 0,6)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div id=\"IDtable-wrap-foot\" class=\"NLM_table-wrap-foot\">\n<p class=\"first last\"><span dir=\"auto\">mEHT: moduleret elektro-hypertermi; CT: kemoterapi; RT: str\u00e5lebehandling; HT: hypertermi; OS: samlet overlevelse; DFS: sygdomsfri overlevelse; CR: komplet respons;<\/span><\/p>\n<\/div>\n<h2><strong>5. Evidens i Aggressive og Recidiverende Sygdomme (Fremvoksende Indikationer)<\/strong><\/h2>\n<h3>5.1. Gliomer (Glioblastoma Multiforme &#8211; GBM og Astrocytom &#8211; AST)<\/h3>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\">Nyere meta-analyser<\/a> antyder, at b\u00e5de mEHT og Tumor Treating Fields (TTF) kan forbedre overlevelsen i glioblastom [10]. *1-\u00e5rs overlevelsen i mHT-studier for nydiagnosticerede patienter var 73% versus 37% i kontrolarmen* (p = 0,0021) [10]. For astrocytomer (AST) viste mHT en signifikant fordel (median OS p\u00e5 72 m\u00e5neder versus 17 m\u00e5neder i den bedste palliative st\u00f8ttegruppe) [11].<\/p>\n<h3>5.2. Bugspytkirtelkr\u00e6ft (Pancreatic Cancer &#8211; PC)<\/h3>\n<p>Et <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\">stort retrospektivt observationelt multicenterstudie<\/a> (N=217) sammenlignede mEHT + CHT med CHT alene.<\/p>\n<ul>\n<li><strong>Overall Survival (OS): OS blev signifikant forbedret i mEHT-gruppen (20 m\u00e5neder, vs. 9 m\u00e5neder i CHT-gruppen, P &lt; 0,001).<\/strong><\/li>\n<li><strong>Progression-Free Survival (PFS): PFS blev ogs\u00e5 signifikant forbedret (7 m\u00e5neder, vs. 5 m\u00e5neder, P &lt; 0,05).<\/strong><\/li>\n<\/ul>\n<hr \/>\n<h2>6. Sikkerhedsprofil og Livskvalitet (QALY): HT&#8217;s H\u00f8je Terapeutiske Indeks<\/h2>\n<p><strong>Fase III-evidens st\u00f8tter overv\u00e6ldende, at HT ikke signifikant \u00f8ger alvorlig toksicitet.<\/strong><\/p>\n<h3>6.1. Analyse af Systemisk Toksicitet (Grad 3\u20134)<\/h3>\n<p>Systematisk analyse bekr\u00e6fter, at HT <strong>ikke forv\u00e6rrer systemisk toksicitet<\/strong> (RR \u2248 1.0 for livmoderhalskr\u00e6ft). Toksicitetsprofilen for endetarmskr\u00e6ft og bugspytkirtelkr\u00e6ft var ogs\u00e5 sammenlignelig.<\/p>\n<h3>6.2. Bivirkninger Specifikke for Hypertermi Modaliteter<\/h3>\n<p>Bivirkninger er overvejende lokale og h\u00e5ndterbare (f.eks. milde forbr\u00e6ndinger). Moduleret RF Hypertermi (mHT) har en s\u00e6rlig gunstig sikkerhedsprofil; bivirkninger blev kun rapporteret i 2,6% af mHT-sessionerne i bugspytkirtelkr\u00e6ftstudiet.<\/p>\n<p><strong>Tabel 3: Sammenligning af Sikkerhed og Toksicitet (HT Integration vs. Standard Pleje)<\/strong><\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Kr\u00e6fttype<\/strong><\/td>\n<td width=\"104\"><strong>Standard Behandling (Kontrol)<\/strong><\/td>\n<td width=\"104\"><strong>Intervention (HT + Standard Behandling)<\/strong><\/td>\n<td width=\"104\"><strong>Grad 3-4 Toksicitetsfund<\/strong><\/td>\n<td width=\"104\"><strong>Klinisk Konklusion<\/strong><\/td>\n<td width=\"104\"><strong>Reference<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Lokalt Fremskreden Livmoderhalskr\u00e6ft<\/td>\n<td width=\"104\">CCRT Alene<\/td>\n<td width=\"104\">CCRT + L-R HT<\/td>\n<td width=\"104\">Ingen signifikant forskel i akut eller sen toksicitet (RR \u2248 1.0)<\/td>\n<td width=\"104\">Gunstigt terapeutisk indeks; Systemiske bivirkninger forv\u00e6rres ikke.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Endetarms-\/Analkr\u00e6ft<\/td>\n<td width=\"104\">CRT<\/td>\n<td width=\"104\">CRT + L-R HT<\/td>\n<td width=\"104\">Sammenlignelig toksicitetsprofil; Ingen stigning i alvorlige GI- eller kutane reaktioner<\/td>\n<td width=\"104\">HT er sikkert i kombination med b\u00e6kken CRT-protokoller.<\/td>\n<td width=\"104\"><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Bl\u00e6rekr\u00e6ft IR NMI (HIVEC-1)<\/td>\n<td width=\"104\">Normotermisk MMC<\/td>\n<td width=\"104\">Hypertermisk MMC<\/td>\n<td width=\"104\">Ingen forskel i alvorlige bivirkninger (p = 0,5)<\/td>\n<td width=\"104\">Alvorlig sygelighed forblev u\u00e6ndret.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2>7. Konklusioner, Klinisk Integration og Fremtidige Retninger<\/h2>\n<h3>7.1. Resum\u00e9 af Definitive Level 1A-Indikationer<\/h3>\n<p><strong>HT har Level 1A-evidens for definitive fordele i overlevelse, sygdomsfri overlevelse og komplet respons i behandlingen af Bl\u00f8ddelssarkom, Lokalt Fremskreden Livmoderhalskr\u00e6ft, Hoved- og Halskr\u00e6ft, Endetarms-\/Analkr\u00e6ft, Melanom (lokoregional sygdom) og Thorakalt Recidiv af Brystkr\u00e6ft [2].<\/strong><\/p>\n<h3>7.3. Lovende Indikationer og Fremtidige Kliniske Studier<\/h3>\n<p>Komparative observationelle data, der indikerer *en fordobling af median OS (fra 9 til 20 m\u00e5neder) for mHT + CHT i metastatisk bugspytkirtelkr\u00e6ft, repr\u00e6senterer et ekstremt st\u00e6rkt klinisk signal.*<\/p>\n<p><strong>Tabel 4: Fremvoksende Indikationer og Fase II\/Observationelle Data (Overlevelsesendepunkter)<\/strong><\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Kr\u00e6fttype (HT Modalitet)<\/strong><\/td>\n<td width=\"104\"><strong>Studietype\/Endepunkt<\/strong><\/td>\n<td width=\"104\"><strong>HT + Standard Pleje (OS\/PFS\/QoL)<\/strong><\/td>\n<td width=\"104\"><strong>Standard Pleje Alene (OS\/PFS\/QoL)<\/strong><\/td>\n<td width=\"104\"><strong>N\u00f8glefund\/P-V\u00e6rdi<\/strong><\/td>\n<td width=\"104\"><strong>Reference<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Bugspytkirtelkr\u00e6ft (mEHT + CHT)<\/td>\n<td width=\"104\">Retrospektiv Komparativ (OS)<\/td>\n<td width=\"104\">Median OS: 20 m\u00e5neder<\/td>\n<td width=\"104\">Median OS: 9 m\u00e5neder<\/td>\n<td width=\"104\">OS signifikant forbedret (77% relativ stigning)<\/td>\n<td width=\"104\">[Fiorentini et al., 2021]<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Nydiagnosticeret Glioblastom (mEHT)<\/td>\n<td width=\"104\">Meta-analyse (1-\u00e5rs OS)<\/td>\n<td width=\"104\">73%<\/td>\n<td width=\"104\">37%<\/td>\n<td width=\"104\">Signifikant OS-fordel (p=0,0021)<\/td>\n<td width=\"104\">(<a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\">https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Astrocytom (mEHT)<\/td>\n<td width=\"104\">Retrospektiv Komparativ (OS)<\/td>\n<td width=\"104\">Median OS: 72 m\u00e5neder<\/td>\n<td width=\"104\">Median OS: 17 m\u00e5neder<\/td>\n<td width=\"104\">OS signifikant forbedret (p=0,0006)<\/td>\n<td width=\"104\">[Fiorentini et al., 2019]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2>8. Ofte Stillede Sp\u00f8rgsm\u00e5l (FAQ) om Onkologisk Hypertermi<\/h2>\n<h3>Q: Er Hypertermi en eksperimentel behandling i Onkologi?<\/h3>\n<p><strong>A:<\/strong> Nej. Hypertermi (HT) er en dokumenteret behandling, der har <strong>Level 1A-evidens<\/strong> (baseret p\u00e5 Fase III randomiserede studier og meta-analyser) for store onkologiske indikationer, s\u00e5som: Bl\u00f8ddelssarkomer, livmoderhalskr\u00e6ft, recidiverende brystkr\u00e6ft, malignt melanom, endetarmskr\u00e6ft, bl\u00e6rekr\u00e6ft og Hoved- og Hals (HNC) tumorer.<\/p>\n<h3>Q: Hvad er den optimale driftstemperatur for Hypertermi?<\/h3>\n<p><strong>A:<\/strong> Den optimale driftstemperatur sp\u00e6nder fra <strong>39\u00b0C til 45\u00b0C<\/strong>. Dette &#8220;terapeutiske vindue&#8221; maksimerer den biologiske sensibiliserende effekt af cancerceller over for kemo- og str\u00e5lebehandling.<\/p>\n<h3>Q: \u00d8ger Hypertermi toksiciteten af kemoterapi eller str\u00e5lebehandling?<\/h3>\n<p><strong>A:<\/strong> Analyse af Fase III-studier bekr\u00e6fter, at tilf\u00f8jelsen af Hypertermi <strong>ikke signifikant \u00f8ger alvorlig systemisk toksicitet (Grad 3-4)<\/strong>. Bivirkninger er overvejende lokale og let h\u00e5ndterbare.<\/p>\n<h3>Q: Hvordan forbedrer Hypertermi str\u00e5lebehandling?<\/h3>\n<p><strong>A:<\/strong> Hypertermi fungerer som en potent radiosensibilisator gennem to n\u00f8glemekanismer: <strong>1)<\/strong> Den h\u00e6mmer DNA-reparationsmekanismer beskadiget af str\u00e5ling, og <strong>2)<\/strong> Den forbedrer blodgennemstr\u00f8mningen og tumoriltningen.<\/p>\n<h3>Q: Hvilke kr\u00e6fttyper drager st\u00f8rst fordel af Hypertermi?<\/h3>\n<p><strong>A:<\/strong> If\u00f8lge Level 1A-evidens er overlevelsesfordele blevet demonstreret for: <strong>Bl\u00f8ddelssarkomer, livmoderhalskr\u00e6ft, recidiverende brystkr\u00e6ft, malignt melanom, endetarmskr\u00e6ft, bl\u00e6rekr\u00e6ft og HNC.<\/strong><\/p>\n<p>Citations<br \/>\n1. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/<\/p>\n<p>2. Full article: Systematic review of the registered clinical trials for oncological hyperthermia treatment &#8211; Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2022.2076292<\/p>\n<p>3. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. &#8211; Jefferson Digital Commons, https:\/\/jdc.jefferson.edu\/cgi\/viewcontent.cgi?article=1070&amp;context=radoncfp<\/p>\n<p>4. Full article: Hyperthermia and immunotherapy: clinical opportunities &#8211; Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2019.1653499<\/p>\n<p>5. Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer &#8211; PMC, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11575926\/<\/p>\n<p>6. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive &#8230;, https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/p>\n<p>7. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8994727\/<\/p>\n<p>8. Full article: Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy &#8211; Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2021.2002435<\/p>\n<p>9. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3 &#8211; PubMed Central, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8984886\/<\/p>\n<p>10. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas &#8211; MDPI, https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880<\/p>\n<p>11.Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study, Retrospective study , Author:<\/p>\n<div class=\"entry-content\">\n<div class=\"container\">\n<div class=\"acf-fields \">\n<div class=\"publ-acf acf-row acf-flex\">\n<div class=\"szerzok\"><span class=\"sz-nev\">Fiorentini G<\/span>\u00a0<span class=\"sz-nev\">Sarti D<\/span>\u00a0<span class=\"sz-nev\">Milandri C<\/span>\u00a0<span class=\"sz-nev\">Dentico P<\/span>\u00a0<span class=\"sz-nev\">Mambrini A<\/span>\u00a0<span class=\"sz-nev\">Fiorentini C<\/span>\u00a0<span class=\"sz-nev\">Mattioli G<\/span>\u00a0<span class=\"sz-nev\">Casadei<\/span>\u00a0<span class=\"sz-nev\">Guadagni S<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>12. Current understanding of modulated electro-hyperthermia in cancer treatment -; Kosin Medical Journal, https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Autoritet og Ekspertise (E-E-A-T): Af Dr. Veronica Iatan, MD, og Cristian Gologan M.S.c, Andromedichyperthermia Terapeutisk Integration af Hypertermi i Moderne Onkologi: En Kritisk Analyse af Fase III-Studier og Meta-Analyser (OS, DFS, CR Endpoints) 1. Resum\u00e9 og Grundl\u00e6ggende Principper for Hypertermi (HT) Onkologisk Hypertermi (HT), defineret som den kontrollerede anvendelse af varme ved temperaturer i intervallet&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[110,887,36],"tags":[353,142,354],"class_list":["post-11188","post","type-post","status-publish","format-standard","hentry","category-nyheder","category-studii-clinice-da","category-uncategorized-da","tag-fase-iii-studier","tag-hypertermi","tag-meta-analyser-da"],"gutentor_comment":1,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts\/11188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/comments?post=11188"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts\/11188\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/media?parent=11188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/categories?post=11188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/tags?post=11188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}